Interferon in the treatment of cutaneous T-cell lymphoma.
about
The optimal use of bexarotene in cutaneous T-cell lymphomaT-cell lymphomas, a challenging disease: types, treatments, and future.Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indicationsPhase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trialCharacterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients.New and established treatment options for mycosis fungoides and Sézary syndrome - an update.Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon-induced apoptosis.Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod.Immune modulators as therapeutic agents for cutaneous T-cell lymphoma.Mycosis fungoides: therapeutic difficulties.Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic LeukemiaManagement of Lymphomas: Consensus Document 2018 by an Indian Expert Group
P2860
Q28305252-A20972C5-D6F7-4D62-B4F0-EAC912346B3AQ30244553-E917C4F8-03A8-40F2-B335-5D58060F8391Q30252152-21E58461-F61D-41F8-A5A8-4910A8ABAFF0Q33746059-36F97E59-3250-47E9-AE6F-2623E4378109Q33930161-D02DC7AB-AD15-4FBC-BCF5-D62AA64070A1Q34516083-598AB798-A436-4293-8434-B9685871F070Q35022833-33D626C1-63DF-4EF8-AC9D-B864AD27044EQ35105819-89216373-4372-44AA-8697-DF7CDF3414E7Q37346462-6BC707DF-A09F-4097-8AC1-CFE8114A5E5DQ38216976-1DB8FFB4-71A8-476E-99E9-5F6DAB60EAC8Q38805440-3F62A9ED-E8C5-4874-A756-C085603BA07CQ39150709-FC3A0123-36B8-4FEE-8C73-ECDC041159D3Q39557726-818364EA-972E-40B1-A4ED-31ACD640B523Q41844919-0EBA1626-D79F-48DA-AD25-18C7C9ECD371Q42665053-BE36E1AB-7AC5-44E8-94F3-2FC96EBAF2BCQ46248185-2A0E3093-23C0-4457-8251-E6421F7A0A0FQ47389863-7A647712-6BAC-4464-9640-7B50ECE1B97EQ48296904-158B15ED-4E5B-45A9-83B9-B9A520E1E2DFQ51484852-6A2E1B97-B75A-426D-A3B8-10AAEDD27EAEQ58749358-0D82CEFC-3FE6-4CC9-A2E0-8918CC7813B0Q58801965-2F60D70C-5364-4812-9D11-5D9E4FF4A10A
P2860
Interferon in the treatment of cutaneous T-cell lymphoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Interferon in the treatment of cutaneous T-cell lymphoma.
@ast
Interferon in the treatment of cutaneous T-cell lymphoma.
@en
type
label
Interferon in the treatment of cutaneous T-cell lymphoma.
@ast
Interferon in the treatment of cutaneous T-cell lymphoma.
@en
prefLabel
Interferon in the treatment of cutaneous T-cell lymphoma.
@ast
Interferon in the treatment of cutaneous T-cell lymphoma.
@en
P2860
P1433
P1476
Interferon in the treatment of cutaneous T-cell lymphoma.
@en
P2093
Elise A Olsen
P2860
P304
P356
10.1111/J.1396-0296.2003.01643.X
P577
2003-01-01T00:00:00Z